Financial Performance - The company's revenue decreased due to project deployment delays caused by the COVID-19 pandemic, leading to a significant reduction in net profit[6]. - The company's operating revenue for 2021 was approximately ¥963.14 million, a decrease of 29.94% compared to ¥1.47 billion in 2020[22]. - The net profit attributable to shareholders was a loss of approximately ¥104.89 million, a significant decline of 4,634.62% from a profit of ¥15.11 million in 2020[22]. - The basic earnings per share for 2021 was -¥0.82, a decrease of 4,200.00% from ¥0.12 in 2020[22]. - The weighted average return on equity was -26.99% in 2021, down from 3.62% in 2020[22]. - The company's total revenue for 2021 was approximately ¥963.14 million, a decrease of 29.94% compared to ¥1.37 billion in 2020[96]. - The net profit attributable to shareholders was -685.23 million yuan, a decrease of 4634.62% year-on-year[69]. - The commercial intelligence segment generated ¥501.02 million, accounting for 52.02% of total revenue, down 15.05% from ¥589.77 million in 2020[96]. - The smart medical segment reported revenue of ¥462.12 million, representing 47.98% of total revenue, a significant decline of 41.13% from ¥785.02 million in 2020[96]. - Domestic sales were ¥583.90 million, which constituted 60.62% of total revenue, reflecting a decrease of 41.75% from ¥1.00 billion in 2020[96]. Strategic Partnerships and Technology Development - The company has established long-term strategic partnerships with several international firms, including Huawei, Baidu, and IBM, to enhance its technological capabilities[7]. - The company plans to continue focusing on five core technologies: IoT, artificial intelligence, big data interaction, microservices framework, and blockchain, to drive innovation in smart healthcare services[8]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technologies and strategies[18]. - The company aims to leverage five core technologies: IoT, artificial intelligence, platform big data interaction, microservice framework, and blockchain to enhance its smart healthcare services[43]. - The company has established long-term strategic partnerships with international firms such as Huawei, IBM, and Intel to drive technological innovation in the smart healthcare sector[43]. Research and Development - The company invested a total of 214.21 million yuan in R&D, accounting for 22.24% of its revenue, with a year-on-year growth of 5.45%[55]. - The company has developed over 60 single-disease data resource libraries and clinical auxiliary robots for diseases such as echinococcosis and breast cancer, leveraging its proprietary THINKGO+ cognitive engine[57]. - The company has completed the development of a clinical decision support system based on a medical knowledge graph, which is expected to significantly advance precision medicine and has a broad market prospect[110]. - The company is working on an artificial intelligence-based clinical decision support system, targeting diseases such as esophageal cancer and congenital heart disease, with a goal of achieving an accuracy rate of no less than 90% in decision support[115]. - The company has completed the development of an AI-based stethoscope system, which aims to improve diagnostic accuracy and enhance the company's core competitiveness in the medical field[116]. Market Trends and Growth Projections - By 2024, the total IT expenditure in China's healthcare industry is projected to reach RMB 104.15 billion, with the healthcare application software solutions market expected to grow to RMB 32.72 billion, reflecting a compound annual growth rate of over 15%[7]. - The company is positioned in the smart healthcare industry, which is expected to grow significantly, with a projected IT spending market size of ¥104.15 billion by 2024[39]. - The RFID industry in China is projected to grow from a market value of 136 billion yuan in 2020 to over 350 billion yuan by 2025, indicating significant growth potential[47]. Operational Challenges - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated in the recent audit report[28]. - The company reported a negative net profit for the last three accounting years when excluding non-recurring gains and losses, indicating ongoing financial challenges[28]. - The company has implemented retrospective adjustments for financial statements from 2019 to 2022 due to accounting errors related to inflated revenue[26]. - The company has recognized a growing market for smart medication systems, with a focus on developing a mass-produced version tailored for domestic use, capitalizing on the increasing number of cardiovascular patients[116]. Governance and Compliance - The company has established a comprehensive governance structure, ensuring compliance with relevant laws and regulations, and conducted two shareholder meetings during the reporting period[168]. - The company has no controlling shareholder, maintaining independence in operations and decision-making processes[168]. - The company has implemented a rigorous impairment testing process for goodwill and other long-term investments to manage potential asset devaluation risks[164]. - The company has maintained compliance with relevant laws and regulations, ensuring the integrity of its governance practices[193]. Future Outlook - The company anticipates a revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[67]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[67]. - The company is committed to enhancing its smart business solutions by utilizing its full industry chain advantages from chip development to system integration[153]. - The company aims to create a seamless service experience for patients through IoT and AI technologies, enabling features like online registration and automated payment[155].

Financial Performance - The company reported a significant loss due to extended delivery cycles and increased costs, resulting in a challenging performance in the overall weak environment [4]. - The company's operating revenue for 2022 was CNY 1,115,911,058.33, representing a 15.86% increase compared to CNY 961,549,939.60 in 2021 [27]. - The net loss attributable to shareholders for 2022 was CNY 877,948,482.50, a decrease of 28.13% from CNY 727,023,296.00 in 2021 [27]. - The net cash flow from operating activities for 2022 was CNY 105,192,708.38, showing a significant decline of 178.48% compared to CNY 134,041,273.63 in 2021 [27]. - The total assets at the end of 2022 were CNY 3,634,654,155.96, a decrease of 24.98% from CNY 4,863,530,760.78 at the end of 2021 [27]. - The net assets attributable to shareholders at the end of 2022 were CNY 1,244,094,346.64, down 41.02% from CNY 2,180,294,680.75 at the end of 2021 [27]. - The company reported a basic and diluted earnings per share of -CNY 1.06 for 2022, a decrease of 29.27% from -CNY 0.87 in 2021 [27]. - The weighted average return on net assets for 2022 was -52.45%, compared to -27.64% in 2021 [27]. - The company reported non-recurring gains of ¥18.92 million in 2022, down from ¥75.59 million in 2021, indicating a decline in non-operating income [38]. - The company achieved a revenue of 1,115.91 million yuan in 2022, representing a year-over-year growth of 15.86% [77]. Market and Business Strategy - The core business focuses on smart healthcare, leveraging IoT, big data, AI, and blockchain technologies to enhance patient safety and clinical efficiency [5]. - The company plans to continue focusing on innovation, differentiated products, and standardized systems to improve customer experience [6]. - The company aims to support the "Thirteenth Five-Year Plan" and the "Action Plan for Promoting High-Quality Development of Public Hospitals (2021-2025)" [6]. - The company is committed to enhancing the comprehensive capabilities of county hospitals, with a target of 1,000 county hospitals achieving tertiary hospital service levels by 2025 [6]. - The company plans to enhance its market expansion strategies and invest in new product development to improve future performance [27]. - The company is actively pursuing strategies to expand its market presence and improve its operational capabilities in response to industry challenges [42]. - The company aims to leverage five core technologies: IoT, artificial intelligence, big data interaction, microservices architecture, and blockchain to drive innovation in smart healthcare services [46]. - The company is focusing on integrating advanced technologies such as AI and IoT to enhance its product offerings in the smart healthcare sector [43]. - The company is committed to building a full industry chain layout centered on smart healthcare, smart business, smart health, and smart elderly care [52]. Research and Development - The company has established over 10 technology innovation research and development centers and has participated in more than 20 national major research projects [6]. - The company has invested CNY 203.77 million in R&D, accounting for 18.38% of its revenue, which represents a year-on-year decrease of 4.87% [66]. - The company is focusing on the development of wireless data transmission systems for smart healthcare, targeting efficiency and error reduction in medication management [114]. - The company has developed a clinical decision support system for esophageal cancer, congenital heart disease, and sepsis, with a goal of achieving an accuracy rate of at least 90% [120]. - The company is developing personalized rehabilitation aids with real-time positioning and fall alert modules, targeting elderly and disabled populations [119]. - The company has developed over 60 single-disease data resource libraries and application service platforms based on its THINKGO medical AI cognitive engine [79]. - The company is actively enhancing its clinical knowledge base and integrated electronic medical record systems, with multiple software versions released in April 2022 [71]. Partnerships and Collaborations - The company has established long-term strategic partnerships with international firms such as Huawei, Baidu, and IBM, positioning itself as a leading provider of smart medical solutions in China [46]. - The company has established stable partnerships with over 300 clients and agents globally, exporting products to more than 70 countries and regions [51]. - The company is collaborating with Yunhai Chain Holdings to integrate blockchain technology into smart medical applications, addressing industry pain points [161]. Regulatory and Compliance - The company is currently under investigation by the China Securities Regulatory Commission for alleged information disclosure violations, which may impact its operations [170]. - The company has implemented a comprehensive internal control system to manage risks and ensure normal business operations [177]. - The company ensures compliance with information disclosure obligations, adhering to principles of fairness, justice, and openness [176]. Governance and Management - The company held 3 shareholder meetings during the reporting period, including 1 annual and 2 extraordinary meetings, ensuring equal treatment of all shareholders [174]. - The board of directors consists of 7 members, including 3 independent directors, meeting the legal requirements for governance structure [175]. - The company has a structured governance framework in place, ensuring compliance with regulations [181]. - The management team includes experienced professionals with varying backgrounds in finance and operations [182]. - The company is focused on maintaining shareholder engagement through regular meetings and transparent communication [180]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 20% to 1.8 billion yuan, driven by new product launches and market expansion efforts [200]. - The company is focusing on market expansion, targeting an increase in market share by 15% in the next fiscal year through strategic partnerships and marketing initiatives [200]. - The management team emphasized the importance of innovation, with 10% of revenue earmarked for research and development in 2023 [200].

| 证券代码：300078 | 证券简称：思创医惠 | 公告编号：2024-054 | | --- | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | | 思创医惠科技股份有限公司 关于 2023 年度计提资产减值准备及核销资产的公告 资产减值准备 244,522.31 元，转出商誉减值准备 7,911,319.62，计入的报告 期间为 2023 年 1 月 1 日至 2023 年 12 月 31 日，明细如下表： 二、本次计提资产减值准备和核销资产的确认标准、计提方法 1、应收账款（应收账款、其他应收款、长期应收款、合同资产）坏账计提 方法： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《企业会计准则第 8 号—资产减值》《上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等有关规定，为真实、准确反映公司财务状 况、资产价值及经营成果，思创医惠科技股份有限公司（以下简称"公司"） 对截至 2023 年 12 月 31 日合并报表范围内的各类资产进行了全面检查和减值测 试，基于谨慎性原则，公司对可能发生减值损失 ...

| 证券代码：300078 | 证券简称：思创医惠 | 公告编号：2024-059 | | --- | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | | 思创医惠科技股份有限公司 关于重要前期会计差错更正及追溯调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次前期会计差错更正采用追溯调整法。思创医惠科技股份有限公司 （以下简称"公司"）对 2019 年至 2022 年度财务报表进行会计差错更正及追 溯调整。 2、本次差错更正不会导致公司已披露的定期报告出现盈亏性质的改变。 公司于 2024 年 4 月 24 日召开第五届董事会第四十次会议、第五届监事会 第二十四次会议，分别审议通过了《关于重要前期会计差错更正及追溯调整的 议案》。同意公司根据《企业会计准则第 28 号——会计政策、会计估计变更和 差错更正》和《公开发行证券的公司信息披露编报规则第 19 号——财务信息的 更正及相关披露》的相关规定，对 2019 年度、2020 年度、2021 年度、2022 年 度的财务报表进行差错更正及追溯 ...

Financial Performance - The company's revenue for Q1 2024 was ¥198,888,851.70, a decrease of 15.42% compared to ¥235,156,485.53 in the same period last year[6] - The net profit attributable to shareholders was -¥67,764,977.31, an improvement of 11.61% from -¥76,663,823.76 year-on-year[6] - The net cash flow from operating activities decreased by 47.20% to ¥25,518,697.95, down from ¥48,334,123.98 in the previous year[6] - The weighted average return on equity was -7.81%, a decrease of 1.78% from -6.03% in the previous year[6] - The company reported a net loss of ¥68,576,893.20 for the current period, compared to a net loss of ¥80,567,340.48 in the previous period, showing an improvement of about 15%[30] - The total comprehensive loss for the current period was ¥68,984,875.95, compared to a loss of ¥85,664,791.57 in the previous period, reflecting an improvement of about 19.5%[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,518,345,759.65, a decline of 2.85% from ¥2,592,337,624.35 at the end of the previous year[6] - The equity attributable to shareholders increased by 10.49% to ¥546,959,564.05, compared to ¥495,038,972.85 at the end of the previous year[6] - The total liabilities decreased to RMB 1,959,138,728.27 from RMB 2,084,592,658.95, indicating a reduction of about 6%[27] - The company’s non-current liabilities decreased to RMB 729,666,802.38 from RMB 846,181,860.46, a decline of about 13.8%[27] Cash Flow - The net cash flow from investing activities surged by 263.97% to ¥169,699,667.33, compared to ¥46,624,978.92 in the same period last year[9] - Cash and cash equivalents at the end of the period increased to ¥482,439,364.81 from ¥425,848,954.45, reflecting a net increase of approximately 13.3%[35] - The company’s investment activities generated a net cash flow of ¥169,699,667.33, compared to ¥46,624,978.92 in the previous period, marking a substantial increase[34] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 44,532[11] - Major shareholder Cangnan Sijia Internet of Things Intelligent Partnership increased its stake from 6.00% to 7.32% by acquiring 11,541,001 shares for a total of 39,890,779.25 RMB between February 9 and March 8, 2024[18] - The company’s major shareholders include Cangnan Sijia with 63,890,185 shares (7.32%), and other significant shareholders include Zhang Yuan and Duan Liping[12] - The company’s stockholder structure indicates a concentration of ownership among a few key investors, which may impact governance and strategic decisions[12] Management and Governance - The company was fined 85.7 million RMB by the China Securities Regulatory Commission for regulatory violations, and the former chairman received a 10-year market ban[14] - The company received a public reprimand from the Shenzhen Stock Exchange for governance issues involving its management[15] - The company’s financial performance and future outlook were discussed, emphasizing the importance of maintaining investor confidence[18] - The company’s former chairman, Zhang Lizhong, resigned on January 4, 2024, and was replaced by Zhu Yiming[16] Operational Changes - The company changed its registered address to Wenzhou, Cangnan, from Hangzhou, to align with its operational needs[19] - The company has not disclosed any new product developments or market expansion strategies in the recent reports[12] Financial Instruments - The company issued 8.17 million convertible bonds with a total value of RMB 81.7 million, with a coupon rate of 1.00%[22] - The conversion price for the convertible bonds was adjusted downwards to RMB 3.58 per share, effective from February 28, 2024[22] - In Q1 2024, the company converted 1,356,308 convertible bonds into 37,885,114 shares, leaving 5,237,622 convertible bonds outstanding[23] Research and Development - Research and development expenses were ¥32,012,601.95, slightly down from ¥33,460,399.84, indicating a decrease of about 4.3%[29] Audit and Compliance - The first quarter report has not been audited[36] - The new accounting standards will be implemented starting in 2024[36]

思创医惠科技股份有限公司 董事会关于独立董事独立性情况的专项报告 思创医惠科技股份有限公司（以下简称"公司"）董事会根据《上市公司独 立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》及《独立董事工作制度》等相关法律、法规和规章制度的规定 和要求，就公司在任独立董事赵合宇先生、刘银先生、梁立先生的独立性情况进 行评估并出具如下专项意见： 经核查，公司独立董事赵合宇先生、刘银先生、梁立先生已向公司出具《独 立董事独立性自查报告》，上述人员未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在任何影响独立董事独立性 的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规章制度中关于 独立董事独立性的要求。 思创医惠科技股份有限公司董事会 2024 年 4 月 26 日 ...

证券代码：300078 证券简称：思创医惠 公告编号：2024-058 债券代码：123096 债券简称：思创转债 思创医惠科技股份有限公司 董事会关于 2023 年度保留意见审计报告涉及事项 2020 年度思创医惠公司及子公司部分交易对手杭州易捷医疗器械有限公司、 杭州闻然信息技术有限公司等多家单位与思创医惠公司原大股东杭州思创医惠 集团有限公司及其关联方存在直接或间接的资金往来，且杭州思创医惠集团有限 公司存在占用上市公司资金的情况；思创医惠公司及子公司以前年度以自有资金 和募集资金向杭州易捷医疗器械有限公司、杭州菲诗奥医疗科技有限公司等多家 公司采购了被服柜、睡眠仪及其他软硬件，其中部分交易方为关联方。截至 2023 年末，思创医惠公司因上述交易等形成的资产账面原值 23,396.91 万元，累计计 提折旧和摊销 8,285.68 万元，因被服柜、睡眠仪等设备闲置累计计提减值准备 11,161.53 万元，账面价值 3,949.70 万元。 的专项说明 思创医惠科技股份有限公司（以下简称"公司"或"思创医惠公司"）聘请 的天健会计师事务所（特殊普通合伙）对公司 2023 年度财务报告出具了保留意 见的审 ...

公司对 2024 年度日常关联交易情况进行了估算，具体情况如下： | 证券代码：300078 | 证券简称：思创医惠 | 公告编号：2024-051 | | --- | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | | 思创医惠科技股份有限公司 关于 2024 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 因生产经营和业务发展需要，思创医惠科技股份有限公司（以下简称"公司"） 及公司控股子公司预计 2024 年度将继续与上海泽信软件有限公司（以下简称"上 海泽信"）发生日常关联交易，拟向上海泽信采购产品的交易金额预计不超过 800 万元；拟向上海泽信销售产品、商品的交易金额预计不超过 800 万元。截至 2023 年 12 月 31 日，公司 2023 年度同类交易预计发生总金额为 4,000 万元，实际发 生总金额为 1,764.04 万元。 公司于 2024 年 4 月 24 日召开第五届董事会第四十次会议、第五届监事会 第二十四次会议，分别审 ...

中信证券股份有限公司 关于思创医惠科技股份有限公司 2023 年度募集资金存放与使用情况的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为思创医 惠科技股份有限公司（以下简称"思创医惠"、"公司"）向不特定对象发行可转 换公司债券的保荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交 易所创业板股票上市规则》等有关规定，对思创医惠 2023 年度募集资金存放与 使用情况进行了审慎核查，并出具核查意见如下： 一、募集资金基本情况 主承销商中信证券股份有限公司采用向不特定对象发行方式，发行可转换公司债 券 8,170,000 张，每张面值为人民币 100.00 元，按面值发行，发行总额为人民币 81,700.00 万元，坐扣承销和保荐费用 999.00 万元后的募集资金为 80,701.00 万元， 已由主承销商中信证券股份有限公司于 2021 年 2 月 1 日汇入公司募集资金监管 账户。另减除律师费、会计师费用、资信评级费和发行手续费等与发行可转换公 司债券直接相关的外部费用 210.62 万元(含税)，加上可予抵扣的增值税进项税额 68.47 万元后，公司本次募集资金净额为 ...

思创医惠科技股份有限公司 2023 年度独立董事述职报告 （赵合宇） 本人作为思创医惠科技股份有限公司（以下简称"公司"）的独立董事，在 2023 年度任职期间，本人严格按照《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《公司章程》《独立董事工作制度》等相关法律、 法规及规范性文件的规定和要求，勤勉尽责、独立谨慎地行使权利，积极出席相 关会议，认真审议董事会各项议案，对公司重大事项发表了独立意见。本人根据 公司实际情况，充分发挥自身专业优势，提出了意见和建议，促进公司规范运作， 切实维护了公司和股东尤其是中小股东的利益，充分发挥了独立董事及相应专门 委员会的作用。 现将本人 2023 年度履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人赵合宇，男，汉族，1966 年出生，中国国籍，无境外永久居留权，会计 学硕士研究生学历，注册会计师，注册税务师。1991 年 4 月至今，历任中国电 子工业总公司副主任科员、电子工业部主任科员、世纪审计事务所副所长、新世 纪会 ...